We upgrade our rating from SELL to MARKET PERFORM as the path toward profitability of FRT’s Long Chau pharmacy chain is becoming clearer — particularly in terms of the positive progress in its opex optimization. In addition, FRT’s share price has corrected 7% in the last three months.